Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights
In early February 2022, we completed our IPO on the Nasdaq Capital Market, raising $16 million in gross proceeds. First Quarter 2022 Financial ResultsCash, cash equivalents and short-term... | May 10, 2022
Christopherm Calabrese Ron Bentsur Exchange Commission Nature Communications Company Contact Optimization Program
Source: marketscreener.com